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The mechanisms by which oral, live-attenuated vaccines protect against typhoid fever 
are poorly understood. Here, we analyze transcriptional responses after vaccination with 
Ty21a or vaccine candidate, M01ZH09. Alterations in response profiles were related 
to vaccine-induced immune responses and subsequent outcome after wild-type 
Salmonella Typhi challenge. Despite broad genetic similarity, we detected differences 
in transcriptional responses to each vaccine. Seven days after M01ZH09 vaccination, 
marked cell cycle activation was identified and associated with humoral immunogenicity. 
By contrast, vaccination with Ty21a was associated with NK cell activity and validated 
in peripheral blood mononuclear cell stimulation assays confirming superior induction of 
an NK cell response. Moreover, transcriptional signatures of amino acid metabolism in 
Ty21a recipients were associated with protection against infection, including increased 
incubation time and decreased severity. Our data provide detailed insight into molecular 
immune responses to typhoid vaccines, which could aid the rational design of improved 
oral, live-attenuated vaccines against enteric pathogens.
Keywords: typhoid, typhoid vaccines, functional genomics, vaccine immunity, Ty21a, nK cell, cell cycle regulation
inTrODUcTiOn
Salmonella enterica serovar Typhi (S. Typhi) is the predominant cause of enteric fever, a non-
specific febrile infection affecting between 9.1 and 17.8 million people globally each year (1–3). 
Transmission between humans occurs by ingestion of faecally contaminated food or water, after 
which S. Typhi invades the gut mucosa and may be taken up by phagocytic cells, before asymp-
tomatic systemic dissemination to the reticuloendothelial system. Individuals presenting with 
typhoid fever develop non-specific symptoms including fever, abdominal pain and headache, and 
bacteremia ensues (4, 5). It remains unclear how innate immunity or the adaptive immune systems 
(following vaccination or prior infection) eradicates S. Typhi after infection. Detailed investigation 
of the molecular host responses to live-attenuated vaccines and interpretation in the context of 
responses seen after human exposure to virulent wild-type S. Typhi may provide useful insights 
informing future vaccine design.
Ty21a is an oral, live-attenuated typhoid vaccine that has been licensed in 1989 and administered 
to a large number of people (6), demonstrating a protective efficacy of 42–96% after three or four 
doses in clinical trials performed in typhoid-endemic regions (7–9). Ty21a has been attenuated 
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by random mutagenesis, resulting in poor infectivity of and 
survival inside host cells such as macrophages (10–12). Other 
oral live-attenuated vaccine candidates in development include 
M01ZH09, which originates from the same Ty2 parent strain 
as Ty21a. By contrast to Ty21a, M01ZH09 has been attenuated 
by two specific deletions of the ssaV and aroC genes, designed 
to prevent systemic spread and rendering the strain replication 
deficient, while retaining macrophage infectivity (13). In clinical 
trials, this vaccine has been shown to be safe and immunogenic, 
leading to robust anti-LPS antibody responses (13–15), which 
previous studies suggested may be a correlate of protection 
following Ty21a vaccination (16). The precise mechanisms 
resulting in protective immunity against typhoid fever after oral 
vaccination are poorly understood, despite its administration to 
millions of people since licensure. While protection mediated 
by inactivated Vi-polysaccharide vaccines is likely to be anti-Vi 
antibody mediated, cell-mediated immunity (CMI) is induced by 
live oral vaccines may also play an important role (17, 18). In par-
ticular, in vitro stimulation of peripheral blood mononuclear cells 
(PBMCs) isolated from Ty21a recipients with S. Typhi antigens 
using autologous antigen-presenting cells indicated multiphasic 
CD8+ T cell responses over months following vaccination (19). 
These reports suggest that oral, live-attenuated vaccines act 
through a complex interaction including induction of protective 
T  cell responses and humoral responses to a broader array of 
S. Typhi antigens.
While the aforementioned studies focused on CD8+ T  cell 
responses, involvement of other cell types in responses to vac-
cination and infection is likely. Indeed, interrogation of responses 
following experimental challenge with S. Typhi Quailes strain 
has revealed activation of regulatory T (Treg) cells during acute 
disease and has highlighted a role for circulating monocytes and 
dendritic cells (DCs) in binding of S. Typhi within 24 h after chal-
lenge (20, 21). While B cells are also activated by Ty21a (22), the 
role of other cell types, including NK cells, in the development 
of protective responses following oral live-attenuated vaccination 
against typhoid remains unknown.
Using a controlled human infection model of typhoid fever, 
we recently evaluated the protective efficacy Ty21a and M01ZH09 
(23, 24). In this study, we describe the transcriptional response 
and investigate how these may relate to the subsequent immune 
response detected in the volunteers. In this context, we explored 
the relationship of the transcriptome signature to the different 
humoral immune responses, post-challenge clinical findings, 
and downstream activation of cell-mediated immune processes, 
identifying profound differences in NK cell activation by the two 
vaccine strains tested.
resUlTs
Differences are evident in the 
Transcriptional Patterns following 
independent immunization with Two  
Oral, live-attenuated Vaccines
To investigate host responses to live-attenuated oral typhoid vac-
cines, we vaccinated healthy adult volunteers with either three 
doses of the licensed vaccine Ty21a (n =  33), a single dose of 
the candidate vaccine M01ZH09 (n = 33), or placebo (n = 33), 
as part of a randomized, double-blinded, placebo-controlled trial 
(24). Gene expression (GEX) profiles were generated based on 
mRNA purified from whole blood before and at multiple time 
points following vaccination. The majority of measurements were 
using samples taken 7 days after completion of vaccines, i.e., at 
D-21, 7 days after the third dose of Ty21a and the first dose of 
M01ZH09 or placebo (Figures 1A,B).
At D-21, we observed moderate differential expression of 
the blood transcriptome in Ty21a vaccine recipients (90 genes) 
relative to baseline, and an even more modest differential per-
turbation in M01ZH09 vaccine recipients (70 genes, p < 0.001; 
Figures 1C,D). Due to the low level of perturbation in placebo 
recipients (29 genes; Figure S1A in Supplementary Material), 
subsequent analyses focused on Ty21a and M01ZH09 groups 
only. Transcriptional perturbation at early time points following 
vaccination (Ty21a: “D-28” and “D-26”; M01ZH09: “D-24”) was 
more pronounced in Ty21a recipients, potentially driven by the 
sequential doses of Ty21a in comparison with the single dose of 
M01ZH09. While we observed only one gene that overlapped 
both time points following Ty21a vaccination, more overlap 
was observed between D-24 and D-21 following M01ZH09 
(Figure  1E). Interestingly, although Ty21a seemed to induce a 
similarly modest magnitude of transcriptional changes, it was 
significantly less immunogenic, as determined by anti-O9:LPS 
and anti-H responses 28  days following vaccination than was 
M01ZH09 (Figure S1B in Supplementary Material) (24).
To interrogate the signaling pathways stimulated by vaccina-
tion, we performed pathway overrepresentation analysis (ORA) 
of genes differentially expressed (DE) compared with baseline 
using the publically available database InnateDB (25). For Ty21a 
recipients, this analysis highlighted differential regulation of the 
pathways involved in the adaptive immune system and mRNA 
splicing. Furthermore, more general signatures of ribosomal 
subunit activity and translation elongation were highly overrep-
resented at the early D-26 time point and decreased at the D-21 
time point. While ribosomal, and translation and elongation 
pathways were also DE soon after M01ZH09, we observed strong 
differential regulation of several pathways associated with cell 
cycle activity at 7 days following vaccination (D-21, Figure 1F). 
Although pathway analysis suggests differential activation of 
distinct molecular patterns compared between the vaccine arms, 
other similarities in expression patterns were observed, specifi-
cally at the earlier time points (D-28, D-26, and D-24) following 
vaccination.
inverse activation of cell cycle and  
nK cells following Oral live-attenuated 
Vaccination
To further interpret the overall molecular pattern underlying the 
GEX following live-attenuated oral vaccination against typhoid, 
we used Gene Set Enrichment Analysis (GSEA). GSEA is a com-
plementary method to pathway ORA that instead of relying on 
threshold values to identify over- or underexpressed pathways or 
modules, employs a ranked list of genes to calculate enrichment 
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FigUre 1 | Continued
FigUre 2 | Gene Set Enrichment Analysis was performed at each time point following Ty21a and M01ZH09 vaccination. (a) Tile graph with significant blood 
transcriptional modules (BTMs) (adjusted p < 0.05) following vaccination (blue: negative enrichment; red: positive enrichment). Non-significant BTMs were set to 
normalized enrichment score (NES) = 0 (gray: not significant). Bar graph to the right indicates the number of significantly enriched BTMs at each time point/group. 
(B) NESs of BTMs at the D-21 time point following vaccination. Middle: scatter plot displaying NES of significantly enriched BTMs (adjusted p < 0.05) following 
either Ty21a (x-axis) or M01ZH09 (y-axis) vaccination. If a BTM was not significantly enriched in one of the two groups, the respective NES was set to 0. Colors 
represent different BTM categories. Dot plots depict enrichment scores of cell cycle (left) and NK cell (right) related modules. Solid dots: p < 0.05.
FigUre 1 | Continued  
Gene expression (GEX) following oral, live-attenuated typhoid vaccination. (a,B) Study design and sample overview for Ty21a (orange; three doses administered at 
D-32, D-30, and D-28) and M01ZH09 (green; one dose administered at D-28). Numbers in circles represent N of which samples were taken at each time point/
assay. Gray shaded time points indicated where no samples were taken. Samples were collected for GEX, antibody serology (Ab), and in vitro infection [peripheral 
blood mononuclear cell (PBMC)] analysis. (c,D) Number of differentially expressed (DE) genes over pre-vaccination baseline following Ty21a (c) and M01ZH09  
(D) vaccination at time points after vaccination corresponding to panel (a,B). (e) Circos plot indicating the overlap of DE genes between each vaccine arm and time 
point. Blue links: overlap between M01ZH09 time points. Purple links: overlap between M01ZH09 and Ty21a. Yellow and red links: overlap between Ty21a time 
points. Red and blue dots indicate up- or downregulation of each gene, respectively. (F) Significant pathways overrepresented by DE genes following Ty21a and 
M01ZH09 vaccination (increasing bubble size depicts increasing significance level).
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scores for modules of interest (26). GSEA was performed using 
14,302 genes ranked by log2 fold change(FC) against a concep-
tual framework of predefined blood transcriptional modules 
(BTMs) previously described by Li et al., with calculation of a 
normalized enrichment score (NES) and significance threshold 
for each module (27).
Shortly after vaccination with two (D-28) or three (D-26) 
doses of Ty21a, significant perturbation of several BTMs was 
observed (BH-adjusted p  <  0.05) (Figure  2A). While some 
BTMs representing monocyte (M11.0 and M118.0) and innate 
response signatures (M.37.0, M16, and M25) were downregu-
lated, several interferon (M127, M111.1, and M75), NK cell (S1, 
M61.0, M61.2, and M7.2), and T cell (M7.0, M7.3, and M223) 
modules were upregulated immediately following Ty21a inges-
tion (Figure 2A). Vaccination with M01ZH09 induced a higher 
number of BTMs at both time points measured (D-24 and 
D-21), compared with any time point after Ty21a vaccination. 
In addition, despite similarities in expression of some cell cycle 
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and IFN modules, M01ZH09 elicited several responses at D-24 
that contradicted those seen at the equivalent earliest time points 
after Ty21a receipt (D-26). These represented upregulation of 
monocyte (M11.0 and M118.0) and innate response (M37 and 
M16) modules and downregulation of T  cell modules (M7.0, 
M7.3, and M223) in the M01ZH09 arm (Figure 2A).
Comparison of BTMs 7 days after completion of vaccination 
(D-21 in both groups) indicated further distinct differences 
between responses to the two oral vaccines. While positive 
enrichment of BTMs reflecting cell cycle control and monocytes 
was measured following M01ZH09, the opposite was observed 
(with negative or lack of enrichment) after Ty21a vaccination 
(BH-adjusted p < 0.05, Figure 2B—middle and left). By contrast, 
modules reflecting NK cell activity were upregulated after Ty21a 
and downregulated after M01ZH09 vaccination (BH-adjusted 
p < 0.05) (Figure 2B—middle and right). Of note, while most 
T cell modules were downregulated at D-21 following M01ZH09 
receipt (and not significantly enriched following Ty21a), pos-
sible important differences were seen in three T  cell-related 
modules. These modules [“mitotic cell cycle in stimulated CD4 
T  cells (M4.5),” “mitotic cell cycle in stimulated CD4 T  cells 
(M4.9),” “cell division (stimulated CD4+ T cells) (M46)”] were 
upregulated in the M01ZH09 group but downregulated in the 
Ty21a group and represent cell division in CD4+ T cells indicat-
ing possible activation of specific T helper responses specifically 
following M01ZH09 vaccination. Overall, this group level GSEA 
has demonstrated interesting similarities and differences in the 
transcriptional response to two oral, live-attenuated typhoid 
vaccines. While transcriptional signatures of T  cell responses 
appeared to be variable, a consistent difference in the expression 
of signatures representing NK  cells was observed between the 
Ty21a and M01ZH09 arms.
To further analyze the expression dynamics of modules among 
participants, we performed single sample GSEA (ssGSEA) at 
day 7 after vaccination (D-21). Plotting the mean expression 
(mean  +  SEM) of BTMs reflecting the cell cycle, NK  cells, 
T cells and B cells highlights the differential expression pattern 
of cell cycle and NK  cell modules between the vaccine groups 
(Figure 3A). Host immune responses to stimuli such as vaccines 
are known to vary between individuals as a result of both environ-
mental and genetic factors (28, 29). To assess this variability, we 
plotted NK modules for each participant following vaccination 
and calculated the inter-decile range for each participant. This 
analysis highlighted the considerable variability in the response 
among the participants (Figure  3B). Overall, however, we 
observed consistent opposite expression of genes in the NK cell 
BTM including inhibitory and activating receptors including 
KIR3DL3, KIR3DL1, KIR2DL3, and KIR2DL4 (Figures 3C,D).
cell cycle is associated with the 
Magnitude of humoral immune 
responses
Because ssGSEA provides enrichment scores for each BTM in 
each participant, these can be used to relate BTM expression to 
immunogenicity measurements (i.e., antibodies 4 weeks follow-
ing vaccination) as well as parameters following challenge. Using 
Spearman’s rank correlation, we observed significant associations 
of cell cycle BTMs expressed at D-21 with antibody responses 
28 days after vaccination, which were positive in M01ZH09 but 
negative in Ty21a recipients (Figure 3E). Moreover, we observed 
positive correlation of BTMs representing inflammation, mono-
cytes and DCs and anti-H responses following Ty21a compared 
with M01ZH09 (Figure 3E). In addition, T cell-related modules 
were negatively associated with antibody responses following 
Ty21a vaccination. Of note, modules associated with B cell sign-
aling and antigen presentation were negatively associated with 
serological responses to this vaccine. These data provide further 
insight into the modular response 7 days after vaccination, and 
the relationship to humoral responses suggesting that cell cycle 
BTMs may be predictive of humoral immunogenicity following 
oral live-attenuated vaccination.
Modular expression after Vaccination is 
associated with Delayed Onset of Disease 
following challenge
Since this study was performed as part of a human challenge model, 
we selected two outcome measures following challenge to be 
correlated with enrichment scores at D-21 following vaccination. 
Time to diagnosis (ttDx) was delayed in participants receiving 
the M01ZH09 vaccine whereas there was no difference in maxi-
mum temperature (Temp) within 14 days following challenge in 
participants of both vaccine arms (24). This analysis showed that 
several modules were associated with post-challenge parameters, 
including “CD28 co-stimulation” (M12) and “enriched in cell 
cycle” (M167) following M01ZH09 vaccination. By contrast, fol-
lowing Ty21a vaccination, we observed BTMs that relate to trans-
membrane transport (M154.1), amino acid transport (M154.0), 
SMAD2/3 signaling (M97), E2F transcription factor (M8), and 
complement activation (M112.1) associated with post-challenge 
parameters. Associations with Temp and ttDx were inverse for 
several modules within respective vaccine arms (Figure 3E—gray 
nodes), showing a positive correlation with Temp but negative 
correlation with ttDx at the same time. Thus, M112.1, M97, and 
M8 expression following vaccination were positively associated 
with higher Temp, but shorter ttDx. By contrast, M12, M154.1, 
and M154.0 expression following vaccination was associated 
with lower Temp and longer corresponding ttDx (Figure  3F). 
These data underline the inverse relationship between disease 
severity markers (Temp) and ttDx of overt clinical disease in the 
challenge model and indicate possible protection indicated by 
module M154.0, M154.1, and M12 expression at time point D-21 
following vaccination.
superior capacity of Ty21a compared 
with M01Zh09 to activate nK cells In Vitro
Given the major differential response in NK cell module activa-
tion between Ty21a and M01ZH09 vaccine recipients, we hypoth-
esized that these vaccine strains might display differences in their 
capacity to activate NK cells in vitro. In vitro infection of PBMCs 
isolated from vaccine-naïve study volunteers (n  =  16) before 
vaccination with either of the two vaccine strains (Figure  4A) 
indicated that Ty21a displayed greater capacity to induce surface 
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FigUre 3 | Continued
FigUre 4 | In vitro infection of peripheral blood mononuclear cells (PBMCs) from study participants. (a) Experimental design. PBMCs harvested from study 
participants at pre-vaccination (D-32: Ty21a; D-28: M01ZH09), 14 days (D-14), and 28 days after vaccination (D0, day of challenge) were infected in vitro with Ty21a 
(orange) or M01ZH09 (dark green). (B) Differential induction of activation markers on NK, T, and NKT cells following in vitro stimulation of PBMCs from vaccine-naïve 
volunteers with Ty21a (orange) and M01ZH09 (green). Multiplicity of infection = 0.1:1. Statistics: paired t-test: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
FigUre 3 | Continued  
Single sample GSEA (ssGSEA) following vaccination at time point D-21. (a) Normalized enrichment score (NES) (mean + SEM) of blood transcriptional modules 
(BTMs) related to NK cells (blue bar), the cell cycle (purple), B cells (pink bar), and T cells (cyan bar) across all participants in the Ty21a (orange) and M01ZH09 
(green) arm at time point D-21 after vaccination is plotted. (B) Tile graph representing the NES for all NK cell-related BTMs for each participant (red: positive NES; 
blue: negative NES). Color bar on the right represents the vaccine group membership. Bar graph along the tile graph signifies the heterogeneity within each 
participant (depicted by inter-decile range). (c) NK cell modules were combined into one network and superimposed with mean gene expression values at time 
point D-21 following Ty21a (top) and M01ZH09 (bottom). (D) Mean expression of genes within the NK cell-related BTMs in the Ty21a and M01ZH09 group at time 
point D-21 following vaccination. (e) Association networks. NESs derived from the ssGSEA at time point D-21 were correlated with antibody responses to 
vaccination and parameters reflecting outcome following challenge [temperature (Temp); time to diagnosis (ttDx)] in Ty21a (left) and M01ZH09 (right) recipients.  
BTM colors: purple: cell cycle. Blue: NK cells. Cyan: T cells. Red: inflammation, monocytes, and dendritic cells. Pink: antibodies, B cells, and antigen presentation. 
Green: platelet activation. Colors of edges represent significance level and Spearman’s rank correlation coefficients (orange: p < 0.05, rho > 0; blue: p < 0.05, 
rho < 0; gray: n.s.). Gray shaded nodes: BTMs associated with post-challenge outcomes. (F) Correlation plot of maximum Temp following challenge and ttDx. 
Modules indicated on the plot represent modules inversely associated with Temp and ttDx. Top left: positive and negative correlation with Temp and ttDx, 
respectively. Bottom right: positive and negative correlation with ttDx and Temp, respectively. Orange: Ty21a recipients; dark green: M01ZH09 recipients.
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expression of NK  cell functional activation markers, including 
CD25 (p < 0.01) and CD107a (p < 0.0001), but not intracellular 
production of IFN-γ (p = 0.08), compared with M01ZH09. We 
also observed activation of these markers by Ty21a in CD3+ T 
and CD3+CD56+ (NKT and γδT) cell populations; however, no 
differences were observed between the two vaccine strains for 
CD107a and CD25 surface expression (Figure 4B).
Following vaccination with specific antigens, NK  cells have 
been shown to mount a rapid effector recall response when re-
exposed to the same antigen (30). To evaluate this phenomenon 
in the context of live-attenuated oral vaccines against typhoid, we 
reexposed PBMCs collected following vaccination (D-14 and D0) 
to the autologous vaccine strain in study participants. Overall, 
recall responses on exposure to the autologous vaccine strain did 
FigUre 5 | Autologous recall responses in peripheral blood mononuclear cells (PBMCs) from individuals post-vaccination. PBMCs harvested from study 
participants at 14 days (D-14) and 28 days after vaccination (D0, day of challenge) were infected in vitro with the autologous vaccine strain and NK cell  
responses measured. Fold-change increases of baseline responses are presented. Statistics: two-sided t-test.
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not differ at 14 days (D-14) or 28 days (D0) after vaccination with 
Ty21a or M01ZH09 (Figure 5). While some participants in the 
M01ZH09 arm appeared to display an enhanced response to the 
in vitro stimulation of post-vaccine PBMCs, the recall responses 
were not significantly increased compared with stimulated 
PBMCs collected from Ty2a vaccine recipients. Similar observa-
tions were made when PBMCs from participants were reexposed 
to the heterologous vaccine strain: no significantly increased recall 
responses were observed when PBMCs isolated from M01ZH09 
and Ty21a recipients to Ty21a or M01ZH09, respectively (Figure 
S2A in Supplementary Material). Finally, we exposed the PBMCs 
to S. Typhi Quailes strain, the strain used in the subsequent chal-
lenge (24). Similar to the previous re-exposure experiments, a 
recall response to this strain was not observed after vaccination 
(Figure S2B in Supplementary Material).
DiscUssiOn
Despite the administration of Ty21a to millions of humans, the 
immune responses induced following immunization with oral, 
live-attenuated vaccines against typhoid fever are still poorly 
understood. Here, we have generated detailed immune response 
profiles following two oral live-attenuated vaccines against 
S.  Typhi, the three-dose Ty21a and the single-dose M01ZH09 
vaccine. In addition to significant differences in humoral immu-
nogenicity 28 days after vaccination, we observed differences in 
the incubation period and clinical severity following subsequent 
infection after experimental oral challenge (24). Our analyses 
uncovered differential transcriptional responses to these broadly 
similar oral vaccines, indicating a predictive relationship between 
transcriptional cell cycle signatures shortly after vaccination and 
humoral immune responses. Moreover, genes reflecting NK cell 
signatures were markedly DE underlining the differences in the 
immunological response induced by the vaccines and offer-
ing novel insight into possible mechanisms associated with 
protection.
Live-attenuated oral typhoid vaccines are thought to mimic 
much of the early infection process conferring protection by 
induction of the same pathways as natural infection but without 
systemic invasion and clinical symptoms. Despite originating 
from the same parent strain Ty2 (10, 13), Ty21a induced greater 
differential GEX than M01ZH09 representing distinct host 
responses with surprisingly little overlap in DE genes and tran-
scriptional pathways between the vaccine strains. We observed 
differential regulation of the adaptive immune system (BCR 
signaling), RNA splicing, PPAR and EGFR1 signaling pathways 
after Ty21a vaccination. Alternative splicing patterns are part 
of transcriptional regulatory mechanisms involved in immune 
responses and in T cell activation (31, 32). This is further sup-
ported by the differential expression of PPAR signaling, which 
has been implicated in T cell differentiation (33) and linking the 
host’s lipid metabolism with differentiation of tissue-resident Treg 
cells (34). Notably, other patterns mostly representing ribosomal 
pathways were similarly expressed at the earlier time points in 
both Ty21a and M01ZH09 vaccine recipients; these were also 
the time points that were most comparable between the two 
arms when accounting for the differences in dosing schedule. To 
further interpret the GEX data, we used GSEA against predefined 
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BTMs (27). In contrast to analysis at the gene level, M01ZH09 
generated a greater modular response following vaccination. 
Because significant enrichment is based on a consistent position-
ing of module-associated genes at the top or bottom end of the 
ranked list, a higher number of significantly enriched BTMs sug-
gest improved interpretability of the list and thus indicate a more 
coherent response. Importantly, the increased enrichment of the 
modular response following M01ZH09 is in agreement with the 
significantly stronger immunogenicity profile of M01ZH09 (24).
At early time points (D-28 and D-26) following vaccination 
with Ty21a, we observed upregulation of a small number of 
T cell-related BTMs, whereas these modules were downregulated 
or not significantly expressed early after M01ZH09 vaccina-
tion. By contrast, a different set of T cell-related modules were 
upregulated following M01ZH09 (D-24 and D-21) whereas 
downregulated or non-significantly expressed following Ty21a. 
These differences may reflect the differences in dosing regimen; 
however, the different type of these T cell modules may suggest 
that M01ZH09 induced signatures of proliferating T cells possibly 
aiding serological responses. Correlation analysis of BTM enrich-
ment scores at D-21 with incubation period and disease severity 
following challenge highlighted protective associations (positive 
correlation with incubation period, negative correlation with 
Temp) of BTMs representing amino acid metabolism and trans-
port (M154.0 and M154.1) after Ty21a vaccination. Alterations 
to the amino acid metabolism likely mirror the high metabolic 
demand during activation of adaptive immune responses, specifi-
cally T cells (35, 36). Indeed, in vitro studies have reported that in 
addition to antigenic T cell receptor stimulation, amino acids can 
provide the secondary activation signal for T cells through the 
metabolic regulator mTORC1 (37) and tempering this pathway 
can skew responses toward T cell memory (38). Intriguingly, mod-
ules correlating with incubation period and Temp were inversely 
related with both post-challenge parameters. This reflects the 
inverse relationship between ttDx and Temp, which is in keeping 
with previous findings of a similar relationship between incuba-
tion period and inflammatory signatures (39). In agreement with 
our data, Ty21a is known to induce multifunctional IFN-γ and 
TNF-α producing CD8+ T cells able to kill S. Typhi infected target 
cells within 2–8 days after vaccination (17, 19). These time points 
are comparable with our study with D-26 and D-21 equating to 2 
and 7 days following the three-dose Ty21a regime, suggesting that 
the transcriptional signals measurable following Ty21a includ-
ing enrichment of some T  cell modules as well as amino acid 
metabolism are indicative of such T  cell responses induced by 
this vaccine. Whether some of the signatures seen in response 
to three doses of Ty21a could be induced by similar, multiple 
dosing of M01ZH09 remains unknown. Finally, because Ty21a 
was more protective than M01ZH09 but induced weaker anti-
body responses, our results emphasize that oral live-attenuated 
vaccines are likely to confer protection predominantly through 
induction of CMI rather than antibody responses.
By contrast, transcriptional signatures of cell cycle activation 
were consistently positively enriched at D-24 (day 4) and D-21 
(day 7) following M01ZH09 (including M4.0, M4.1, M4.2, M4.5, 
M4.7, and M103). Intriguingly, while we observed robust correla-
tions of cell cycle modules with anti-O9:LPS and anti-H antibody 
responses 28 days after vaccination, B cell and T cell modules 
were negatively associated with serological responses. Since in 
whole-blood transcriptomics change in GEX can be related to 
changes in cellular composition of the blood, this observation 
possibly reflects the migration of cells to the lymphoid and/or 
gut mucosal tissues (40, 41) and thus a net downregulation of 
such modules. In turn, positive correlations between cell cycle 
modules and antibody responses 28 days after vaccination sug-
gest proliferation of plasma cells and therefore predict serologi-
cal immune responses, similarly seen with responses following 
acute typhoid fever (39). Moreover, such GEX profiles have been 
reported to be enriched 1, 3, and 7 days following influenza vac-
cination (42) and associated with anti-circumsporozoite protein 
antibody induction following RTS,S vaccination (43). These data 
in conjunction with reports that plasma cell responses generally 
peak around day 7 after vaccination with conjugate vaccines 
(PCV7 and MenC) suggest that transcriptional cell cycle sig-
natures may provide an early peripheral blood marker of B cell 
generation (39, 44, 45).
We observed a striking induction of modules reflecting 
NK cell-related signatures following Ty21a vaccination. NK cells 
are a key cell type required for the production of IFN-γ, which 
is critical for protection in murine models of Salmonella infec-
tion (46). While some differences in modular responses may be 
attributable to the differences in dose regimen between Ty21a and 
M01ZH09, the NK cell signatures were remarkably consistent in 
its positive enrichment in Ty21a vaccinees even within 2 days of 
two or three doses. NK cells have been implicated in responses 
to live and attenuated vaccines; however, little is known of their 
specific role following vaccination, nor is it known whether live-
attenuated oral vaccines stimulate and activate NK cells (30, 47). 
Using an in  vitro infection model of PBMCs from naïve study 
volunteers stimulated with the vaccine strains, we indeed demon-
strated a superior capacity of Ty21a to induce NK cell activation 
markers. This is of interest as NK  cells can mount rapid recall 
responses upon re-exposure to the same vaccine antigen thus giv-
ing grounds for a role in protection by vaccination at the mucosal 
level (30, 47, 48). In our study, however, neither autologous nor 
heterologous re-exposure of PBMCs isolated from vaccine recipi-
ents at 14 and 28 days after vaccination showed recall responses 
following in vitro stimulation.
While we identified post-vaccination signatures associated 
with delayed onset of typhoid fever and decreased disease sever-
ity, these data should be interpreted with caution. The identifica-
tion of surrogates of protection is not trivial as the attack rate in 
the challenge model is approximately 65%, thus complicating the 
identification of individual participants protected by the vaccine 
and the 35% who remain well throughout the 14-day challenge 
period. Therefore, other measures such as incubation period or 
Temp maybe more suitably for correlation with vaccine responses. 
The disparate responses triggered by the two vaccines may be 
based on one or more of several fundamental differences between 
the strains. First, the different attenuation methods resulting in 
altering capability to invade and survive inside host cells may be 
the reason for the differences in host responses observed. Second, 
an important difference is the dosing regimen as well as vaccine 
formulation (Ty21a enteric-coated capsule versus M01ZH09 oral 
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suspension), which, although difficult to control in these post hoc 
experiments, may also result in divergent response profiles and 
overlapping kinetic of host cell stimulation. Our study design, 
however, prohibits the interrogation of whether M01ZH09 would 
increase activation of T  cell-related pathways if administered 
as a similar, multiple three-dose regime. Three doses of Ty21a 
are likely to have marked effects on the mucosal environment 
and thus impact subsequent host responses. Moreover, non-
vaccine-related aspects such as sampling time points following 
vaccination may confound the results observed (42, 43). Finally, 
unlike to Ty21a, M01ZH09 is (variably) able to express Vi due 
to the presence of the viaB operon, therefore possibly affecting 
host–pathogen interactions; however, Vi responses to the vaccine 
were low (24).
This study provides the first detailed account of the transcrip-
tional host response following oral, live-attenuated vaccination 
against typhoid fever. Our results indicate important novel 
aspects of immune responses necessary for developing protec-
tion after oral vaccination against typhoid. Strategies to improve 
our understanding of these responses in better detail and their 
importance in combatting gut mucosal pathogens may provide 
important insights into the design of improved live-attenuated 
oral vaccines against enteric pathogens.
MaTerials anD MeThODs
study Design and Participants
A randomized, double-blind, placebo-controlled trial was 
performed at the Centre for Clinical Vaccinology and Tropical 
Medicine (Churchill Hospital, Oxford, UK) to assess the protec-
tive efficacy of a single dose of M01ZH09 (oral suspension and 
liquid formulation) compared with placebo against S. Typhi chal-
lenge 28  days after vaccination (NCT01405521), as previously 
described (24). Three doses of Ty21a (enteric-coated capsules) 
were given to a positive comparator arm. The trial was sponsored 
and monitored by the Oxford University Clinical Trials and 
Research Governance office, approved by NRES South Central—
Oxford A (11/SC/0302) and conducted in accordance with the 
principles of the International Conference of Harmonization, 
Good Clinical Practice guidelines.
After study initiation (November 2011), an independent Data 
and Safety Monitoring Committee (DSMC) reviewed clinical 
and laboratory data relating to patient safety (months 1, 5, and 
8) and interim unblinded analyses of vaccine efficacy (months 5 
and 8). No changes to the study protocol or participant eligibility 
were recommended (24). Four weeks following vaccination, par-
ticipants ingested 1.2 g/120 mL NaHCO3[aq] followed by 30 mL 
of 1–5 × 104 CFU of S. Typhi Quailes strain using an ambulant 
study design (23). Following challenge participants were fol-
lowed over 14 days, after which a 2-week course of antibiotics 
(ciprofloxacin, 500 mg twice daily, 14 days) commenced unless 
participants developed overt clinical disease, in which case anti-
biotic treatment commenced immediately. Criteria for typhoid 
diagnosis were either microbiological (≥1 positive blood culture 
collected after day 5) and/or clinical (fever ≥38°C sustained for 
≥12 h) (23, 24).
geX array Profiling
Peripheral venous blood (3 mL) was collected in Tempus blood 
RNA tubes (Applied Biosystems) at baseline (pre-vaccination 
controls) (n = 66) for all participants. For individuals randomized 
to receive Ty21a (three-dose schedule) blood was collected at 4 
(D-28; n = 9) and 6 days (D-26; n = 9) after the first dose of Ty21a, 
and 7 days following the final (third) dose of the Ty21a vaccine 
(D-21; n = 20). For individuals randomized to receive M01ZH09 
(single dose), blood was collected 4 days (D-24; n = 10) and 7 days 
(D-21; n =  30) following M01ZH09 vaccination (Figure  1A). 
Samples from the placebo arm were also collected at baseline 
(D-28; n = 8), 4 days (D-24; n = 9), and 7 days (D-21; n = 8) 
thereafter. Total RNA was extracted from all samples using the 
Tempus™ Spin RNA Isolation kit (Life Technologies). 50 ng of 
RNA was used for hybridization into Illumina HT-12v4 bead-
arrays (Illumina Inc.) at the Wellcome Trust Sanger Institute, UK, 
and fluorescent probe intensities captured with GenomeStudio 
software (Illumina Inc.).
Data Processing and identification  
of De genes
Differential gene transcription was assessed by analysis of changes 
in transcript abundance in whole-blood samples collected dur-
ing the study. Raw data were quantile normalized, background 
subtracted and log2-transformed using the Bioconductor suite 
in R (Version 3.0.1) (49). Transcripts represented by more than 
one probe on the array were collapsed using the probe with the 
highest mean expression for each gene using the collapseRows() 
function of the WGCNA package in R (50). The collapsed dataset 
was then filtered to include only probes significantly detected 
(p < 0.05) in 60% of all samples, yielding 14,302 genes. This pre-
processed dataset was used for all subsequent analyses. Quality 
control was performed using the arrayQualityMetrics() function 
in R (51) and led to the exclusion of 14 samples. DE genes were 
determined by fitting a linear regression model including post-
vaccination time point and date on which the array was run as 
covariates, and using participant number as blocking variable 
to ensure pairwise analysis using the limma-package in R (52). 
Contrasts were generated between each time point and pre-
vaccination baselines.
gene set enrichment analysis
Expression patterns following vaccination were analysed using 
GSEA in R. Gene lists, consisting of 14,302 genes derived as 
described in the Section “Data Processing and Identification of 
Differentially Expressed Genes,” were ranked by average FC and 
applied to the GSEA algorithm (53). Briefly, NESs of BTMs previ-
ously described by Li et al. (27) were calculated by evaluating the 
overrepresentation of module genes at the extremes (i.e., top or 
bottom) of the ranked gene list and nominal p-values calculated 
using a permutation test procedure (26). As this method can be 
applied to any ranked gene list, we adapted the analysis to calcu-
late enrichment scores on a sample-by-sample basis (ssGSEA). In 
this analysis, per participant FCs at D-21 were calculated using 
each participant’s respective pre-vaccination baseline sample. 
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Resulting lists was then ranked by FC and applied to the GSEA 
algorithm. BTMs, which were significantly enriched (p < 0.01) in 
≥40% of the samples and only annotated BTMs were included in 
subsequent analyses.
antibody responses
Vaccine responses were determined by measuring anti-LPS 
(O9:LPS) and anti-flagellin (H-antigen) IgM, IgA, and IgG 
antibodies using ELISA before and 28 days after vaccination, as 
previously described (24).
Blood Mononuclear cell (PBMc)  
In Vitro infection Model
Peripheral blood mononuclear cells were isolated from study 
participants pre-vaccination (D-32 Ty21a; D-28 M01ZH09), 
and at 14 (D-14) and 28 (D0) days after vaccination and stored 
in liquid nitrogen. For further analysis, samples were thawed, 
seeded at 2 ×  105 cells/well in 96-well tissue culture plates in 
RPMI +  10% fetal bovine serum (FBS) and rested for 2–3  h. 
Frozen sucrose stocks of Ty21a and M01ZH09 grown to log-
phase in Luria-Bertani broth were thawed and bacteria washed 
twice in phosphate-buffered saline before resuspension in 
RPMI + 10% FBS. Bacterial suspensions were added to PBMC 
in vitro at a multiplicity of infection (MOI) of 0.1:1. A low MOI 
was chosen to avoid maximal responses in order to interrogate 
increased recall responses following stimulation of PBMCs from 
vaccinated individuals. Gentamicin was added at 200 µg/mL 1 h 
post-infection to kill extracellular bacteria. Recombinant human 
(rh) IL12 (5 ng/mL) and rhIL18 (50 ng/mL) were used as a positive 
control. Following addition of bacteria or cytokines, PBMCs were 
cultured at 37°C, 5% CO2 for 15 h before addition of Golgistop 
and Golgiplug according to the manufacturer’s directions, before 
further culturing for 3 h.
Flow cytometry
Peripheral blood mononuclear cells were washed and stained 
with antibodies against cell surface markers CD3 (BD 
Biosciences), CD56 (BioLegend), CD107a (BD Biosciences), 
and CD25 (eBioscience). Subsequently cells were fixed and per-
meabilized (BD Cytofix/Cytoperm) before intracellular staining 
of IFNγ (BioLegend). Flow cytometric analysis was performed 
on a BD FACSAria flow cytometer collecting an average of 
60,354 events (minimum: 50,000). Gating of cell populations 
was performed as follows: single events → live cells → lympho-
cytes →  T  cells (CD3+CD56−), NKT  cells (CD3+CD56+), and 
NK cells (CD3−CD56+). Expression of surface markers CD107a 
and CD25 was determined for each cell population through 
comparison with FMOs run in each experiment. Expression 
of the intracellular cytokine IFNγ was determined for each cell 
population through comparison with a sample stained with an 
isotype control antibody run in each experiment (Figure S3A 
in Supplementary Material). For each cell subpopulation, at 
least 102 events were collected (Figure S3B in Supplementary 
Material). All data analysis was performed using FlowJo v10 
(FlowJo, LLC).
statistical analysis
To identify modules associated with immunogenicity and 
parameters following challenge, we performed Spearman’s 
rank correlation relating NESs for each participant and mod-
ule to antibody responses 4 weeks following vaccination and 
maximum Temp within 14 days after challenge. For ttDx was 
defined as hours from challenge until antibiotic treatment com-
menced and participants not reaching the diagnostic criteria 
following challenge were censored at 337.2 h (14.05 days) after 
challenged. All statistical analysis was performed in R (version 
3.2.4) (54) and association networks visualized in Cytoscape 
v3.2.5 (55).
DaTa DePOsiTiOn
Gene Expression Omnibus GSE100665.
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